『BioTalk Unzipped』のカバーアート

BioTalk Unzipped

BioTalk Unzipped

著者： Gregory Austin
無料で聴く

BioTalk Unzipped, hosted by Gregory Austin and Dr. Chad Briscoe, unzips the stories behind medical progress through candid, intelligent, and often entertaining conversations with leaders across biotechnology, pharmaceuticals, medical technology, clinical research, bioanalysis, and drug development. Each episode explores the science, strategy, setbacks, breakthroughs, and human stories shaping the future of medicine. From first-in-human trials and biomarkers to oncology, rare disease, AI, regulatory strategy, and emerging therapeutic technologies, BioTalk Unzipped makes complex life science topics engaging, accessible, and relevant. The show feels like the conversation you would want to overhear after a great scientific conference: thoughtful, unscripted, curious, and grounded in real-world experience. We bring listeners inside the decisions, discoveries, and personal journeys behind the therapies and technologies that may one day reduce suffering and improve lives.BioTalk Unzipped 生物科学 科学 経済学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey

    Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey
    2026/08/08
    Why is gene therapy still so difficult to manufacture at scale after decades of progress?Phillip Ramsey, Chief Technical Officer at Sangamo Therapeutics, joins BioTalk Unzipped for a candid conversation about one of the central challenges facing advanced therapies: turning extraordinary science into reproducible, scalable medicines.Thank You to Our SponsorsLeucentra - https://leucentra.com/Inspired by Science. Empowered by IT. Leucentra provides specialized IT consulting and services for life sciences and healthcare, helping organizations use technology more effectively to support innovation.TruTechnologies - https://trutechnologies.ai/Clinical Trial Execution, Live. TruTechnologies provides live clinical trial execution technology that gives sponsors greater visibility into protocol activities, samples, and study data as they happen.About This EpisodeRecorded onsite at the AAPS National Biotechnology Conference in Boston, Phillip explains why gene therapy manufacturing has not yet reached the maturity of monoclonal antibody production.As technologies have evolved across retroviral vectors, lentiviral vectors, adenovirus, AAV, lipid nanoparticles, and other advanced modalities, development teams have repeatedly been required to rethink fundamental manufacturing and analytical questions.Phillip discusses why analytics are critical, why experience across multiple manufacturing lots and products matters, and why there simply is no shortcut to developing the scientific knowledge necessary to manufacture advanced therapies reliably.He also reflects on the uncertainty of biotechnology.Early in his career, Phillip was walking down a hallway when his CFO asked if he had cashed his paycheck.When he said no, she told him not to.It's a remarkable story that captures something rarely discussed about biotechnology: behind transformative science are people willing to operate through considerable uncertainty while trying to build something that has never existed before.Gregory and Phillip Discuss• Viral vector manufacturing and scale-up• Why analytics are essential to gene therapy development• AAV manufacturing challenges• Lentiviral vectors and other evolving delivery technologies• Lipid nanoparticles and changes in advanced therapy manufacturing• Why gene therapy cannot simply adopt the established monoclonal antibody manufacturing playbook• Building process knowledge across lots and products• Career resilience in biotechnology• Progress across AAV, CAR-T, and other advanced therapies• Gene therapy affordability• The importance of therapeutic durability• Outcomes-based payment models for advanced therapiesPhillip's message for scientists and industry leaders is straightforward: don't assume the manufacturing problem has already been solved simply because a technology has existed for decades.The field is still evolving, and some knowledge cannot be shortcut.About Phillip RamseyPhillip Ramsey is Chief Technical Officer at Sangamo Therapeutics and brings more than 35 years of experience across biotechnology and pharmaceutical manufacturing, technical development, operations, quality, and advanced therapies.Connect with Phillip Ramsey:https://www.linkedin.com/in/phillip-ramsey-a2074711/Sangamo Therapeutics:https://www.sangamo.com/Connect With BioTalk UnzippedGregory Austin on LinkedIn:https://www.linkedin.com/in/gregoryaustin1/Dr. Chad Briscoe on LinkedIn:https://www.linkedin.com/in/chadbriscoe/BioTalk Unzipped:https://www.biotalkunzipped.com/BioTalk Unzipped unzips, unlocks, and uncovers the stories behind medical progress through conversations with scientists, executives, entrepreneurs, and innovators advancing biotechnology, pharmaceuticals, and medical technology.Recorded onsite at the AAPS National Biotechnology Conference in Boston.Special thanks to AAPS and Rebecca Stauffer for supporting the BioTalk Unzipped interview series.
    続きを読む 一部表示
    11 分
  • Her Daughter’s Brain Tumor Turned Her Into a Biotech Founder | Tracy Ryan

    Her Daughter’s Brain Tumor Turned Her Into a Biotech Founder | Tracy Ryan
    2026/07/20
    A mother’s search for answers to her daughter’s relentless brain tumor led her into natural killer cell biology, cancer immunotherapy, and biotech entrepreneurship.Sponsored by Leucentra, https://leucentra.com/ Inspired by science, empowered by IT. Leucentra helps life science and healthcare organizations evaluate, implement, and get more value from technology that supports innovation.Tracy Ryan, co-founder of NKore BioTherapeutics and former chief communications officer, joins Gregory Austin and Dr. Chad Briscoe to explain how her daughter Sophie’s pediatric brain tumor transformed her from a parent searching for options into a cancer advocate, research fundraiser, and biotechnology founder.The conversation examines the scientific reasoning that moved Tracy from medical cannabis advocacy toward NK-cell immunotherapy. She describes an immune-system finding involving Sophie’s natural killer cells, the work of the late UCLA scientist Dr. Anahid Jewett, and the development of an experimental allogeneic NK-cell platform designed to enhance immune activity without genetic engineering.The episode also explores the practical realities of translating an early scientific hypothesis into a therapeutic program, including donor selection, cell persistence, manufacturing, treatment outside the United States, regulatory requirements, clinical evidence, and the difficulty of raising capital for an emerging cell-therapy company.At the center of the discussion is a difficult question: how do scientists, founders, regulators, and families preserve urgency when patients need better options, while still requiring the controlled evidence needed to determine whether a therapy is safe and effective?What you will learn:• How Sophie’s pediatric brain tumor changed the direction of Tracy Ryan’s life • Why natural killer cells are important in immune surveillance and cancer biology • What differentiates allogeneic NK-cell approaches from CAR-T and CAR-NK therapies • How NKore’s experimental platform was designed to activate donor-derived NK cells • Why persistence, donor biology, manufacturing, and lymphodepletion matter in cell therapy • Why early human observations must remain distinct from controlled clinical-trial evidence • How regulatory pathways and capital constraints shape whether promising science reaches patients • What parents facing pediatric cancer need from the scientific and medical communityAbout Tracy Ryan:Tracy Ryan is a pediatric cancer advocate, entrepreneur, public speaker, and biotechnology co-founder. She formerly served as chief communications officer of NKore BioTherapeutics.Her daughter Sophie was diagnosed with a brain tumor during infancy, leading Tracy and her family into more than a decade of advocacy, research support, fundraising, and therapeutic exploration. Tracy and her husband also established Saving Sophie to support pediatric cancer research and help families pursue care. Their family’s experience with medical cannabis was featured in the documentary Weed the People.Connect with Tracy Ryan: https://www.linkedin.com/in/tracyryan23/Connect with Gregory Austin: https://www.linkedin.com/in/gregoryaustin1/Connect with Dr. Chad Briscoe: https://www.linkedin.com/in/chadbriscoe/Watch more BioTalk Unzipped episodes: https://www.youtube.com/@BioTalkUnzipped/videosVisit BioTalk Unzipped: https://www.biotalkunzipped.comLearn more about NKore BioTherapeutics: https://www.nkore.comSupport Saving Sophie: https://www.savingsophie.orgThis episode is brought to you by founding sponsor Lucentra. Lucentra provides information technology consulting for life science and healthcare organizations, helping teams modernize infrastructure, strengthen security, and build scalable technology environments that support scientific innovation.Subscribe to BioTalk Unzipped for conversations with the scientists, founders, regulators, and business leaders shaping the future of medicine.Medical and scientific disclaimer:This conversation is provided for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment guidance. The therapies and outcomes discussed may be investigational, preliminary, or based on individual experience. Early observations do not establish safety or efficacy. Patients and caregivers should consult qualified healthcare professionals before making medical decisions.#CancerImmunotherapy #NKCells #PediatricCancer
    続きを読む 一部表示
    1 時間 4 分
  • The Future of Oncology Drug Development | Dr. Lakshmi Amaravadi

    The Future of Oncology Drug Development | Dr. Lakshmi Amaravadi
    2026/06/11

    Oncology drug development is becoming more complex, and bioanalysis can no longer be treated as simple drug measurement.

    Sponsored by Leucentra, https://leucentra.com/

    Inspired by science, empowered by IT. Leucentra helps life science and healthcare organizations evaluate, implement, and get more value from technology that supports innovation.

    In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe speak with Dr. Lakshmi Amaravadi, Head of Oncology Bioanalysis at AstraZeneca, live from AAPS PharmSci 360 in San Antonio.

    Dr. Amaravadi unpacks why biomarker validation is not one-size-fits-all, how context of use should guide scientific decision making, and why fit-for-purpose validation matters in modern oncology drug development.

    The conversation explores:

    00:00 Why oncology bioanalysis is becoming more complex

    02:12 FDA biomarker validation guidance and industry response

    04:27 What “fit for purpose” means in practice

    06:38 PK assay validation vs biomarker assay validation

    07:52 What drives Dr. Amaravadi’s work in translational science

    10:48 Why validation is not a checkbox exercise

    12:19 Advice for young scientists entering bioanalysis

    15:12 Why oncology drug development is uniquely complex

    18:17 ADCs, bispecifics, T-cell engagers, and conditional T-cell engagers

    19:38 Why bioanalysis now requires understanding biology

    20:46 Dr. Amaravadi’s path from molecular biology to bioanalysis

    24:34 Critical reagent management in complex oncology assays

    26:42 Validation, qualification, and context of use

    29:03 Final thoughts from AAPS PharmSci 360

    This episode is especially relevant for scientists, bioanalytical leaders, translational researchers, clinical pharmacologists, oncology development teams, biomarker scientists, and anyone working at the intersection of drug development, assay validation, and precision medicine.

    Dr. Amaravadi discusses how oncology programs now involve ADCs, bispecifics, T-cell engagers, conditional T-cell engagers, complex linkers, multiple measurable species, immunogenicity considerations, and biomarker strategies that require deeper biological understanding. As she explains in the episode, the future of oncology bioanalysis is not simply measuring what is present. It is understanding what the measurement means in the context of the biology and the development decision.

    Follow BioTalk Unzipped for conversations with leaders in biotech, pharma, bioanalysis, clinical development, translational science, regulatory strategy, and the future of medicine.

    Guest

    Dr. Lakshmi Amaravadi

    https://www.linkedin.com/in/lakshmi-amaravadi/

    Hosts

    Gregory Austin

    https://www.linkedin.com/in/gregoryaustin1/

    Dr. Chad Briscoe

    https://www.linkedin.com/in/chadbriscoe/

    Sponsor: Leucentra

    Related Links

    Celerion

    https://www.celerion.com/
    続きを読む 一部表示
    30 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません